	US 12,295,938 B2
	Composition for treating castration-resistant prostate cancer, comprising quassinoids
Jeong Hoon Kim, Seoul (KR); Byong Chang Jeong, Seoul (KR); and Sue Jin Moon, Seoul (KR)
Assigned to SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR); and RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, Gyeonggi-do (KR)
Appl. No. 17/606,582
Filed by SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR); and RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY, Gyeonggi-do (KR)
PCT Filed May 22, 2020, PCT No. PCT/KR2020/006670 § 371(c)(1), (2) Date Oct. 26, 2021, PCT Pub. No. WO2020/246737, PCT Pub. Date Dec. 10, 2020.
Claims priority of application No. 10-2019-0066278 (KR), filed on Jun. 4, 2019; and application No. 10-2020-0057894 (KR), filed on May 14, 2020.
Prior Publication US 2022/0218660 A1, Jul. 14, 2022
Int. Cl. A61K 31/37 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/37 (2013.01) [A61P 35/00 (2018.01)]

4 Claims

1. A method for treating a castration-resistant prostate cancer, the method comprising:

a step of administering to the subject a pharmaceutical composition comprising at least one quassinoid selected from the group consisting of bruceine A, brusatol, and bruceantin.